{"id":992841,"date":"2026-08-10T10:12:22","date_gmt":"2026-08-10T14:12:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/"},"modified":"2026-08-10T10:12:22","modified_gmt":"2026-08-10T14:12:22","slug":"myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/","title":{"rendered":"Myriad Genetics (MYGN) Securities Investigation Notice – Levi & Korsinsky"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughly $206-208 million, then cut full-year revenue guidance by about $90 million at the midpoint and suspended adjusted EBITDA guidance. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors. <\/i>\n <\/p>\n

\n NEW YORK<\/span>, Aug. 10, 2026<\/span> \/PRNewswire\/ — Myriad Genetics (NASDAQ: MYGN) shares fell after the Company reported Q2 2026 revenue of approximately $190.7 million — down roughly 11% year over year and 7% to 8% below Wall Street consensus of about $206-208 million — and simultaneously cut full-year 2026 revenue guidance to $770-$790 million from approximately $860-$880 million. If you suffered a loss on your Myriad Genetics investment, you are encouraged to click here to submit your information <\/a> . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com <\/a> \u00a0or by telephone at (212) 363-7500.<\/p>\n

\n

\n \"Levi\n <\/p>\n<\/p><\/div>\n

Alongside the revenue cut, the Company lowered gross margin expectations and suspended its adjusted EBITDA guidance entirely. The previously issued adjusted EBITDA range was $37 million to $49 million. Management attributed the shortfall to reimbursement pressure, collections issues, lower average revenue per test, and weaker prenatal performance.<\/p>\n

The timing is central to the investigation. On May 5, 2026, Myriad Genetics reiterated its full-year 2026 revenue guidance range of $860 million to $880 million. That range was reduced by approximately $90 million at the midpoint roughly three months later. The Company’s Q1 2026 Form 10-Q, filed May 6, 2026, reported trade accounts receivable of $123.8 million as of March 31, 2026, compared with $115.3 million as of December 31, 2025, and net cash used in operating activities of $15.7 million.<\/p>\n

Shareholders who lost money on MYGN are encouraged to submit their loss information here <\/a> \u00a0or call (212) 363-7500.<\/p>\n

\n ABOUT LEVI & KORSINSKY, LLP <\/b> \u00a0— Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report.<\/p>\n

Frequently Asked Questions About the MYGN Investigation<\/p>\n

\n Q: What is the MYGN securities investigation about? <\/b> \u00a0A: A securities investigation is pending concerning Myriad Genetics (NASDAQ: MYGN) regarding potentially materially false or misleading statements. Shares fell after the Company reported Q2 2026 revenue of approximately $190.7 million, missing consensus by 7% to 8%, and cut full-year 2026 revenue guidance to $770-$790 million from approximately $860-$880 million while suspending adjusted EBITDA guidance.<\/p>\n

\n Q: Who is eligible to participate in the MYGN investigation? <\/b> \u00a0A: Investors who purchased MYGN stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.<\/p>\n

\n Q: Which statements are being investigated as potentially misleading? <\/b> \u00a0A: The investigation concerns whether Myriad Genetics made materially false or misleading statements regarding its full-year 2026 revenue and adjusted EBITDA outlook and the reimbursement, collections, and prenatal testing trends underlying that outlook.<\/p>\n

\n Q: What do MYGN investors need to do right now? <\/b> \u00a0A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com <\/a> \u00a0or (212) 363-7500.<\/p>\n

\n Q: What documents do I need to participate? <\/b> \u00a0A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.<\/p>\n

\n Q: What if I already sold my MYGN shares — can I still recover losses? <\/b> \u00a0A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought MYGN and sold at a loss may still participate in the investigation.<\/p>\n

\n Q: What if my MYGN losses are small — is it still worth contacting a lawyer? <\/b> \u00a0A: Yes. There is no minimum loss amount required to participate in the investigation.<\/p>\n

\n Q: What does it cost me to participate? <\/b> \u00a0A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs.<\/p>\n

CONTACT:<\/p>\n

Levi & Korsinsky, LLP<\/p>\n

Joseph E. Levi, Esq.<\/p>\n

Ed Korsinsky, Esq.<\/p>\n

33 Whitehall Street, 27th Floor<\/p>\n

New York, NY 10004<\/p>\n

\n jlevi@levikorsinsky.com\u00a0<\/a>\n <\/p>\n

Tel: (212) 363-7500<\/p>\n

Fax: (212) 363-7171<\/p>\n

Attorney Advertising. Prior results do not guarantee similar outcomes.<\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/myriad-genetics-mygn-securities-investigation-notice—levi–korsinsky-302845706.html<\/a><\/p>\n

SOURCE Levi & Korsinsky<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughly $206-208 million, then cut full-year revenue guidance by about $90 million at the midpoint and suspended adjusted EBITDA guidance. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors. NEW YORK, Aug. 10, 2026 \/PRNewswire\/ — Myriad Genetics (NASDAQ: MYGN) shares fell after the Company reported Q2 2026 revenue of approximately $190.7 million — down roughly 11% year over year and 7% to 8% below Wall Street consensus of about $206-208 million — and simultaneously cut full-year 2026 revenue guidance to $770-$790 million from approximately $860-$880 million. If you suffered a loss on your Myriad Genetics investment, you are encouraged … <\/p>\n

Continue reading “Myriad Genetics (MYGN) Securities Investigation Notice – Levi & Korsinsky”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-992841","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMyriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughly $206-208 million, then cut full-year revenue guidance by about $90 million at the midpoint and suspended adjusted EBITDA guidance. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors. NEW YORK, Aug. 10, 2026 \/PRNewswire\/ — Myriad Genetics (NASDAQ: MYGN) shares fell after the Company reported Q2 2026 revenue of approximately $190.7 million — down roughly 11% year over year and 7% to 8% below Wall Street consensus of about $206-208 million — and simultaneously cut full-year 2026 revenue guidance to $770-$790 million from approximately $860-$880 million. If you suffered a loss on your Myriad Genetics investment, you are encouraged … Continue reading "Myriad Genetics (MYGN) Securities Investigation Notice – Levi & Korsinsky"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T14:12:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS650751\/Levi-and-Korsinsky-Logo.jpg?id=OA2834360\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Myriad Genetics (MYGN) Securities Investigation Notice – Levi & Korsinsky\",\"datePublished\":\"2026-08-10T14:12:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\\\/\"},\"wordCount\":708,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS650751\\\/Levi-and-Korsinsky-Logo.jpg?id=OA2834360\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\\\/\",\"name\":\"Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS650751\\\/Levi-and-Korsinsky-Logo.jpg?id=OA2834360\",\"datePublished\":\"2026-08-10T14:12:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS650751\\\/Levi-and-Korsinsky-Logo.jpg?id=OA2834360\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS650751\\\/Levi-and-Korsinsky-Logo.jpg?id=OA2834360\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Myriad Genetics (MYGN) Securities Investigation Notice – Levi & Korsinsky\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/","og_locale":"en_US","og_type":"article","og_title":"Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky - Market Newsdesk","og_description":"PR Newswire Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughly $206-208 million, then cut full-year revenue guidance by about $90 million at the midpoint and suspended adjusted EBITDA guidance. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors. NEW YORK, Aug. 10, 2026 \/PRNewswire\/ — Myriad Genetics (NASDAQ: MYGN) shares fell after the Company reported Q2 2026 revenue of approximately $190.7 million — down roughly 11% year over year and 7% to 8% below Wall Street consensus of about $206-208 million — and simultaneously cut full-year 2026 revenue guidance to $770-$790 million from approximately $860-$880 million. If you suffered a loss on your Myriad Genetics investment, you are encouraged … Continue reading \"Myriad Genetics (MYGN) Securities Investigation Notice – Levi & Korsinsky\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-10T14:12:22+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS650751\/Levi-and-Korsinsky-Logo.jpg?id=OA2834360","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Myriad Genetics (MYGN) Securities Investigation Notice – Levi & Korsinsky","datePublished":"2026-08-10T14:12:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/"},"wordCount":708,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS650751\/Levi-and-Korsinsky-Logo.jpg?id=OA2834360","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/","name":"Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS650751\/Levi-and-Korsinsky-Logo.jpg?id=OA2834360","datePublished":"2026-08-10T14:12:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS650751\/Levi-and-Korsinsky-Logo.jpg?id=OA2834360","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS650751\/Levi-and-Korsinsky-Logo.jpg?id=OA2834360"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-mygn-securities-investigation-notice-levi-korsinsky\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Myriad Genetics (MYGN) Securities Investigation Notice – Levi & Korsinsky"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=992841"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992841\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=992841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=992841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=992841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}